Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

Hepatology

Volumn 40, Issue 5, 2004, Pages 1222-1225

  Yokohama, Shiro ^a   Yoneda, Masashi ^b   Haneda, Masakazu ^a   Okamoto, Satoshi ^a   Okada, Mituyoshi ^a   Aso, Kazunobu ^a   Hasegawa, Takenao ^a   Tokusashi, Yoshihiko ^a   Miyokawa, Naoyuki ^a   Nakamura, Kimihide ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; FERRITIN; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FERRITIN BLOOD LEVEL; HEPATITIS; HISTOPATHOLOGY; HUMAN; LIVER CELL DAMAGE; LIVER FIBROSIS; MALE; MALLORY BODY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; FERRITINS; HEPATITIS; HUMANS; HYPERTENSION; IRON; LIVER; LIVER CIRRHOSIS; LOSARTAN; MALE; MIDDLE AGED; NECROSIS; OSMOLAR CONCENTRATION; RECEPTORS, ANGIOTENSIN; TRANSAMINASES; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 7044222556     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20420     Document Type: Article

References (17)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
2. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. HEPATOLOGY 1990;11:74-80.
3. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. HEPATOLOGY 2003;38:413-419.
4. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-α1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001;15:1667-1672.
5. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. HEPATOLOGY 2003;38:1008-1017.
6. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. HEPATOLOGY 2001;34:745-750.
7. Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K. The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000;18:1605-1610.
8. Ishizaka N, Saito K, Mitani H, Yamazaki I, Sata M, Usui S, et al. Iron overload augments angiotensin II-induced cardiac fibrosis and promotes neointima formation. Circulation 2002;106:1840-1846.
9. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. HEPATOLOGY 2003;37:1202-1219.
10. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. HEPATOLOGY 2004;39:188-196.
11. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
12. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998;114:842-845.
13. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-614.
14. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318.
15. Nagy P, Schaff Z, Lapis K. Immunohistochemical detection of transforming growth factor-beta 1 in fibrotic liver diseases. HEPATOLOGY 1991;14:269-273.
16. Matsuoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. HEPATOLOGY 1990;11:599-605.
17. Washington K, Wright K, Shyr Y, Hunter EB, Olson S, Raiford DS. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. Hum Pathol 2000;31:822-828.